CHANGMAO BIO announced its interim results, with a loss attributable to shareholders of 25.79 million yuan, an increase of 37.28% year-on-year
CHANGMAO BIO announced its mid-year results for 2025, with revenue of approximately 272 million yuan, a year-on-year decrease of 13.23%; the loss attributable to shareholders of the company was 25.79 million yuan, a year-on-year increase of 37.28%; the loss per share was 0.049 yuan. The decline in performance was mainly affected by external factors such as geopolitical conflicts and uncertainty in tariff policies, as well as lower-than-expected demand for downstream products of maleic anhydride and increased interest expenses
According to the Zhitong Finance APP, CHANGMAO BIO (00954) announced its mid-term performance for 2025, with revenue of approximately 272 million yuan, a year-on-year decrease of 13.23%; the loss attributable to shareholders of the company was 25.79 million yuan, a year-on-year increase of 37.28%; the loss per share was 0.049 yuan.
The announcement stated that the main factors affecting the performance decline were: 1. Disruptions from external factors such as geopolitical conflicts and uncertainties in tariff policies. In addition, the demand for downstream products of maleic anhydride was lower than expected, and the release of new production capacity led to changes in the supply-demand pattern, indirectly affecting the prices and profitability of the group's main products; and 2. An increase in interest expenses in the consolidated statement of comprehensive income due to a decrease in the amount of capitalized interest expenses for qualifying assets
